Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous DC and NK cells (China Medical University)
- Development stage
- Unknown
- Lead developer
- China Medical University Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous DC and NK cells (China Medical University) is a cell-based immunotherapy regimen being investigated for the treatment of advanced or metastatic gastrointestinal tumors. The therapy involves the ex vivo expansion and activation of a patient's own dendritic cells (DCs) and natural killer (NK) cells derived from peripheral blood. Dendritic cells are professional antigen-presenting cells that capture tumor antigens and present them to T cells to initiate a specific anti-tumor immune response. NK cells are innate lymphoid cells capable of recognizing and lysing tumor cells without prior sensitization. This autologous cell combination is typically administered intravenously in conjunction with various PD-1 checkpoint inhibitors (such as pembrolizumab or nivolumab) to synergistically enhance immune-mediated tumor clearance in patients with locally advanced or metastatic digestive tract cancers.
- Other names
- NK-CellDC-CellAutologous Dendritic CellsAutologous Natural Killer CellsNK-Cell or DC-Cell
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Autologous DC and NK cells (China Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous DC and NK cells (China Medical University).